Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711775 | 1.00 | CCR1 (0.51) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL2875531 | 0.90 | CCR1 (0.61) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL2875529 | 0.90 | CCR1 (0.61) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL2874393 | 0.89 | CCR1 (0.51) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL5323539 | 0.89 | NR1H2 (0.52) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL5241351 | 0.87 | CCR1 (0.50) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4708622 | 0.87 | CCR1 (0.49) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL3465752 | 0.87 | OPRK1 (0.51) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL13163056 | 0.87 | OPRK1 (0.51) | CCR1SUV39H2NR1H2NR1H3ALK | |
| SCHEMBL3465610 | 0.86 | CCR1 (0.49) | CCR1SUV39H2NR1H2NR1H3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | CCR1 807/4885SUV39H2 433/4885NR1H2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.